logo
The Veterinary Cooperative (TVC) Announces New Partnership with Norbrook to Bring Felanorm™ to Independent Veterinary Practices

The Veterinary Cooperative (TVC) Announces New Partnership with Norbrook to Bring Felanorm™ to Independent Veterinary Practices

Business Wire12-05-2025

CHICAGO--(BUSINESS WIRE)--The Veterinary Cooperative (TVC), the largest group purchasing organization supporting independent veterinary practices, is excited to announce a new partnership with Norbrook Animal Health. This collaboration focuses on Felanorm™, Norbrook's innovative solution designed to support hyperthyroidism in cats.
Felanorm™ is a game-changing product developed to help manage feline hyperthyroidism. It is easy to administer with a honey-flavored liquid formula allowing for more accurate dose titration.
'We are thrilled to partner with Norbrook to bring Felanorm™ to our members,' said Kim London, Director of Strategic Partnerships at TVC. 'Hyperthyroidism is a widespread condition that affects many cats, and Felanorm™ provides a trusted solution to help manage it effectively. This partnership continues our commitment to bringing high-quality, impactful products to the independent veterinary community.'
'Norbrook and TVC have established a new partnership to enhance support of independent veterinarians with differentiated and novel solutions like Felanorm™,' said Brian Hopkins, VP of North America Sales and Marketing. 'We're excited to work alongside a group that shares our commitment to accessible innovation and better patient outcomes.'
About The Veterinary Cooperative (TVC)
The Veterinary Cooperative (TVC) is the largest veterinary GPO, serving nearly 4,000 member locations across the United States. TVC is a member-owned organization dedicated to supporting independent veterinary practices. By leveraging the collective buying power and expertise of its members, TVC helps clinics reduce costs, access innovative resources, and strengthen their business operations. Focused on education, and community engagement, TVC empowers its members to thrive while maintaining their independence and values. For more information, visit www.tvc.coop.
About Norbrook Animal Health
Norbrook® is a global leader in veterinary pharmaceuticals, committed to providing high-quality, affordable solutions for animal health. With a strong portfolio of products for both companion animals and livestock, Norbrook supports veterinarians with products to enhance patient care and practice success. For more information, visit www.norbrook.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CommScope Announces FiberREACH and CableGuide 360 Solutions for SYSTIMAX Portfolio
CommScope Announces FiberREACH and CableGuide 360 Solutions for SYSTIMAX Portfolio

Business Wire

time27 minutes ago

  • Business Wire

CommScope Announces FiberREACH and CableGuide 360 Solutions for SYSTIMAX Portfolio

CLAREMONT, N.C.--(BUSINESS WIRE)-- CommScope (NASDAQ: COMM), a global leader in network connectivity, today announced the unveiling of the FiberREACH™ solution and the launch of CableGuide 360™ platform. Both fall within CommScope's SYSTIMAX® 2.0 portfolio—the FiberREACH solution is designed to help enterprise network providers quickly and reliably extend power and connectivity to support more devices and applications at the edge. CableGuide 360 platform will help providers to properly organize and protect the cables and patch cords. "Our customers are looking for trusted, extended-reach solutions and a more reliable cable management platform and we have listened.' ~Koen ter Linde, SVP and president, Connectivity & Cable Solutions, CommScope. Formerly known as CommScope's Powered Fiber Cable System (PFCS), the FiberREACH portfolio builds on this innovative solution by offering enhanced functionality while satisfying established customer requirements. The FiberREACH portfolio utilizes a range of hybrid cabling solutions to provide gigabit speeds to the network edge. As edge devices have evolved, the need for additional power has become essential; CommScope's FiberREACH portfolio now delivers up to 90W of power to the edge, supporting both power- and data-hungry devices. With these innovations, the FiberREACH platform meets the full range of Power over Ethernet (PoE) standards. The new CableGuide 360 platform, a class-leading suite of cable management solutions, is designed to protect copper and fiber cabling infrastructure with simplified installation that accelerates and densifies deployments. As adds and changes become more difficult, this solution is incredibly flexible and provides cable protection and application support in managing and protecting vertical and horizontal patching applications. 'Our customers are looking for trusted, extended-reach solutions and a more reliable cable management platform and we have listened,' said Koen ter Linde, SVP and president, Connectivity & Cable Solutions, CommScope. 'CommScope continues to enhance the SYSTIMAX 2.0 portfolio to adapt to the growing demands of global enterprise networks. FiberREACH and the CableGuide 360 platform represents a step forward in the cabling, cabling management and connectivity that our customers need to push more power and data to the edge. These solutions build on our unmatched end-to-end expertise and performance warranty offerings—giving our customers one more reason to choose CommScope to extend their networks.' FiberREACH Extending cabling innovation: Building on the highly successful GigaREACH™ XL portfolio, the FiberREACH platform utilizes a range of fiber types and copper gauges to provide customer-specific solutions. Edge power: Support for legacy, new and future architectures providing up to 90W PoE, with one power supply panel feeding up to 32 devices simultaneously. Compact, scalable: High-density performance that supports passive as well as active optical network architectures. Warrantied performance: End-to-end solutions with a 25-year extended product and application warranty. Fully PoE-compliant and compatible with Spanning Tree Protocol (STP) for redundant fiber connections and greater reliability. 90W PoE: Provides more power where needed, up to 350 meters away. CableGuide 360 Warrantied cable protection: support for higher cable densities and protection for copper and fiber cabling infrastructure. Faster, simpler installation: Designed for faster deployment and simpler management without extensive product training or technical expertise. Zero-U capacity and flexibility: Optimized for space efficiency in the vertical cable manager, with the ability to host multiple 19' panels vertically and half-width panels horizontally. Range of design options: Available in white, silver and black in variable widths and heights. The CableGuide 360 solution will be available globally late summer. The enhanced FiberREACH 90W PoE solution is also available globally. For more information, please visit the CommScope website. CommScope and the CommScope logo are registered trademarks of CommScope and/or its affiliates in the U.S. and other countries. For additional trademark information see All other product names, trademarks and registered trademarks are property of their respective owners. About CommScope: CommScope (NASDAQ: COMM) is pushing the boundaries of technology to create the world's most advanced wired and wireless networks. Our global team of employees, innovators and technologists empower customers to anticipate what's next and invent what's possible. Discover more at Follow us on LinkedIn and X. Sign up for our press releases and blog posts. This press release includes forward-looking statements that are based on information currently available to management, management's beliefs, as well as on a number of assumptions concerning future events. Forward-looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, which could cause the actual results to differ materially from those currently expected. In providing forward-looking statements, the company does not intend, and is not undertaking any obligation or duty, to update these statements as a result of new information, future events or otherwise. Source: CommScope

Tandem Diabetes Care Announces t:slim X2 ™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States
Tandem Diabetes Care Announces t:slim X2 ™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States

Business Wire

time2 hours ago

  • Business Wire

Tandem Diabetes Care Announces t:slim X2 ™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. 'This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott's FreeStyle Libre 3 Plus sensors worldwide.' - John Sheridan, president and chief executive officer of Tandem Diabetes Care. 'Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems to fit their unique healthcare and lifestyle needs,' said Dr. Jordan Pinsker, chief medical officer of Tandem Diabetes Care. 'The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology.' The FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the Tandem t:slim mobile app, providing users with multiple, convenient ways to access their current glucose trend. The t:slim X2 insulin pump is powered by Control-IQ+ technology, the latest generation of Tandem's advanced hybrid closed-loop algorithm, which adjusts insulin every 5 minutes based on predicted glucose values. It's the only system with the unique AutoBolus™ feature that calculates and delivers a correction bolus to help with missed meal boluses.* Control-IQ+ is easy to start, use, and personalize, and this latest integration works with the FreeStyle Libre 3 Plus sensor and extends its benefits to even more people with diabetes. 'This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott's FreeStyle Libre 3 Plus sensors worldwide,' said John Sheridan, president and chief executive officer of Tandem Diabetes Care. 'We look forward to expanding access to our t:slim X2 users outside of the U.S. beginning later this year.' When available, Tandem will email eligible users in the U.S. with more information.† About Tandem Diabetes Care Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2 #TandemMobi and #TandemDiabetes. Follow Tandem Diabetes Care on Facebook at Follow Tandem Diabetes Care on LinkedIn at Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, our ability to provide the software update for current t:slim X2 pump users and the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These statements are subject to numerous risks and uncertainties, including our ability to sustain commercial scale manufacturing of the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software, our ability to operate and maintain a system to facilitate online training for existing t:slim X2 pump customers upgrading their existing devices, and the risk that we may encounter other challenges that may delay the availability of the software update for current t:slim X2 pump users or the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These and other risks are identified and described in greater detail under the 'Risk Factors' heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors. Important Safety Information – FreeStyle Libre Systems Product for prescription only; for Important Safety Information, please visit Important Safety Information – Tandem Diabetes Care RX ONLY. The t:slim X2 pump with interoperable technology (the pump) and Control-IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater. Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of Type 1 diabetes mellitus in persons 2 years of age and greater and of Type 2 diabetes mellitus in persons 18 years of age and greater. WARNING: Control-IQ+ should not be used in anyone under the age of 2 years old with Type 1 diabetes or under the age of 18 years old with Type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely. Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit for additional important safety information. © 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, t:slim X2, t:slim, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other third-party marks are the property of their respective owners. * If glucose values are predicted to be above 180 mg/dL (or 10.0 mmol/L), Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL (or 6.1 mmol/L) and delivers 60% of that value. † Future updates for all or some Tandem products may not be developed and may not be offered everywhere and would be subject to applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion.

Kioxia Broadens 8th Generation BiCS FLASH™ SSD Portfolio with High-Performance Data Center NVMe™ SSDs to Maximize GPU Utilization in AI and HPC (High-performance computing) Workloads
Kioxia Broadens 8th Generation BiCS FLASH™ SSD Portfolio with High-Performance Data Center NVMe™ SSDs to Maximize GPU Utilization in AI and HPC (High-performance computing) Workloads

Business Upturn

time6 hours ago

  • Business Upturn

Kioxia Broadens 8th Generation BiCS FLASH™ SSD Portfolio with High-Performance Data Center NVMe™ SSDs to Maximize GPU Utilization in AI and HPC (High-performance computing) Workloads

By Business Wire India Published on June 20, 2025, 09:45 IST TOKYO, Japan: Kioxia Corporation, a world leader in memory solutions, today announced the prototype development and demonstration of its new KIOXIA CD9P Series PCIe® 5.0 NVMe™ SSDs. These next-generation drives are the latest SSDs built with Kioxia's 8th generation BiCS FLASH™ TLC-based 3D flash memory. 8th generation BiCS FLASH™ features CBA (CMOS directly Bonded to Array) technology, a breakthrough architecture that significantly boosts power efficiency, performance, and storage density[1], while doubling the capacity available per SSD compared with the previous generation model[2]. This press release features multimedia. View the full release here: KIOXIA CD9P Series High-Performance Data Center NVMe SSDs to Maximize GPU Utilization in AI and HPC Workloads As GPU-accelerated AI servers drive up the demands on storage infrastructure, maintaining high throughput, low latency, and consistent performance is critical — including keeping valuable GPUs highly utilized. The KIOXIA CD9P Series is purpose-built for these next-generation environments, delivering the speed and responsiveness required by AI, machine learning and HPC (high-performance computing) workloads to ensure GPUs stay fed with data and operating at maximum efficiency. The CD9P Series leverages Kioxia's most advanced 3D flash memory to date, featuring a CBA-based architecture that reduces heat generation, enhances thermal management, and delivers greater overall value through improved performance and power metrics and total cost of ownership. KIOXIA CD9P Series drives deliver 4-corner performance improvements of up to approximately 125% in random write, 30% in random read, 20% sequential read, and 25% in sequential write speeds compared to the previous generation[2]. Furthermore, performance per watt of power consumption has improved by approximately 60% in sequential read, 45% in sequential write, 55% in random read, and 100% (2x) in random write[2]. (Applies to the 15.36 terabyte (TB) model) KIOXIA CD9P Series SSD highlights include (preliminary and subject to change): PCIe ® 5.0, NVMe™ 2.0, NVMe-MI™ 1.2c compliant 5.0, NVMe™ 2.0, NVMe-MI™ 1.2c compliant Open Compute Project Datacenter NVMe™ SSD specification v2.5 support (Not all requirements) Form factors: 2.5-inch 15 mm thickness, EDSFF E3.S Read-intensive (1 DWPD) and mixed-use (3 DWPD) endurances Sequential performance (128 KiB/QD32) – 14.8 GB/s Read and 7 GB/s Write Random performance (4KiB) – 2,600 KIOPS (QD512) Read and 750 KIOPS (QD32) Write 2.5-inch capacities up to 61.44 TB and E3.S capacities up to 30.72 TB CNSA 2.0algorithm support [3] (Prepared for the threat posed by quantum computers) KIOXIA CD9P Series SSDs are now sampling to select customers and will be showcased at HPE Discover 2025, taking place June 23-26 in Las Vegas. Notes[1] Compared to the 6th generation BiCS FLASH™[2] Compared to the KIOXIA CD8P Series [3] The KIOXIA CD9P Series supports Leighton-Micali Signature (LMS) algorithm acknowledged by CNSA 2.0[4] as a digital signature algorithm to prevent firmware tampering in preparation for threats to conventional cryptographic algorithms posed by quantum computers. Advanced Encryption Standard (AES-256) with a key length of 256 bits, which is the data encryption algorithm used in CD9P, is also acknowledged by CNSA 2.0. [4] CNSA2.0: Commercial National Security Algorithm Suite 2.0 *2.5-inch indicates the form factor of the SSD and not its physical size.*Read and write speed may vary depending on various factors such as host devices, software (drivers, OS etc.) and read/write conditions. *Performance is preliminary and subject to change without notice. *Definition of capacity: Kioxia Corporation defines a kilobyte (KB) as 1,000 bytes, a megabyte (MB) as 1,000,000 bytes, a gigabyte (GB) as 1,000,000,000 bytes, a terabyte (TB) as 1,000,000,000,000 bytes, and a kibibyte (KiB) is 1,024 bytes. A computer operating system, however, reports storage capacity using powers of 2 for the definition of 1GB = 2^30 bytes = 1,073,741,824 bytes and 1TB = 2^40 bytes = 1,099,511,627,776 bytes and therefore shows less storage capacity. Available storage capacity (including examples of various media files) will vary based on file size, formatting, settings, software and operating system, and/or pre-installed software applications, or media content. Actual formatted capacity may vary.*A kibibyte (KiB) means 2^10, or 1,024 bytes. *IOPS: Input Output Per Second (or the number of I/O operations per second) *NVMe and NVMe-MI are registered or unregistered trademarks of NVM Express, Inc. in the United States and other countries.*PCIe is a registered trademark of PCI-SIG.*HPE is a trademark of Hewlett Packard Enterprise Company and/or its affiliates. *Other company names, product names and service names may be trademarks of third-party companies. About Kioxia Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with 'memory' by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems. Customer Inquiries:Kioxia GroupGlobal Sales Offices *Information in this document, including product prices and specifications, content of services and contact information, is correct on the date of the announcement but is subject to change without prior notice. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store